ReviewNature reviews. Genetics2026
Redefining cellular reprogramming with advanced genomic technologies.
Review in Nature reviews. Genetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- In Vivo Direct Reprogramming: Current Progress and Future Prospects from Mechanisms to Therapeutic Application.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- Article
- Transcriptional landscape of direct reprogramming toward the hematopoietic lineage.bioRxiv : the preprint server for biology · 2026Article
- Synthetic developmental engineering of human liver organogenesis.Development (Cambridge, England) · 2026Review
- Computational blueprints for cell fate programming.Stem cell reports · 2026Review
- Clinical translation of epigenome editing technologies.Current opinion in biomedical engineering · 2026Article
- Transcription factor collaboration enables precise T cell state engineering.bioRxiv : the preprint server for biology · 2026Article
- RNA-seq and ATAC-seq reveal candidate genes and regulatory networks underlying exogenous ABA-enhanced abiotic stress tolerance in Gossypium hirsutum.TAG. Theoretical and applied genetics. Theoretische und angewandte Genetik · 2026Article
- Induced pluripotent stem cell reprogramming: methodological evolution and challenges in clinical translation.Frontiers in cell and developmental biology · 2026Review
- Bone marrow mesenchymal stem cells and adipocytes in haematological malignancies.Oncology reviews · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
Manipulating cell identity through transcription factor-mediated reprogramming, induced pluripotency or directed differentiation holds promise for disease modelling and regenerative medicine. Yet the cells produced by these methods often do not fully recapitulate the molecular and functional characteristics of their native counterparts. Immaturity, low fidelity and heterogeneity remain barriers, limiting reliability for modelling human disease and therapeutic use. Recent advances in single-cell genomic technologies, integrative computational frameworks and emerging molecular recording tools are beginning to reveal the mechanisms underlying incomplete or inefficient reprogramming and highlight tractable failure points. Together, these approaches could support mechanism-guided protocol design and stepwise gains in fidelity, maturity and purity, potentially moving engineered cells towards clinical relevance and informing design principles for next-generation reprogramming strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.